Crispr Therapeutics AG ( ($CRSP) ) has risen by 9.03%. Read on to learn why. Crispr Therapeutics AG has seen its stock price rise by 9.03% over ...

Syntax Bio, a synthetic biology company programming the next generation of cell therapies, has published new research in ...

For years, Yale researchers David Breslow and Mustafa Khokha have worked together with a similar challenge in their ...

Rare diseases pose unique challenges in the medical field, often affecting a small but vulnerable population with limited treatment options. The Rare Disease Challenge (RaDiChal) is a groundbreaking ...

CRISPR's gene therapy, Casgevy, faces operational challenges and stiff competition from Lyfgenia, impacting its market adoption. The initial commercial rollout of gene therapies requires the ...

Despite a challenging CASGEVY launch, high cash burn, and an almost 10% YTD share count growth, CRISPR’s pipeline breadth and ...

Higher yields, greater resilience to climatic changes or diseases—the demands on crop plants are constantly growing. To ...

2023 was an important year for patients with sickle cell disease. Prior to CRISPR, the only cure for the life-long ailment was a bone marrow transplant, which is notoriously dangerous and costly. This ...

CRISPR technology, a revolutionary tool in genetic engineering, has empowered Lambert's iGEM team to tackle a significant health issue: Lyme disease, which affects nearly half a million Americans ...